Upstream Bio, Inc.
UPB
NASDAQ·Healthcare·Biotechnology·Mkt cap $327.1M
$6.01
▼ -1.15%
P/E
-2.07
Mkt Cap
$327.1M
52-Wk Range
$5.77–$33.68
52-Week Range
$5.77 - $33.68
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 67.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Differentiated TSLP receptor inhibition mechanism targeting key inflammatory pathway
- Monoclonal antibody platform with established manufacturing and safety profiles
- Focus on severe respiratory disease indications with limited current treatment options
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Clinical trial advancement and regulatory milestone achievements for verekitug
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-6.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying UPB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 11, 2026
Reported EPS of -$0.73 vs -$0.74 consensus (+1.9% surprise). Revenue of $773.0K vs $561.4K expected (+37.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1.9%
Revenue trend · last 8Q
—
+36%
-12%
+84%
+13%
+9%
+83%
-18%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$607.0K
$613.0K
$566.0K
$937.0K
$683.0K
$668.0K
$1.0M
$773.0K
Margins · last 8Q
Gross
0.0%
Profit
-5136.1%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 3, 2026
vs Industry
How UPB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related